Pseudokinase drug intervention: A potentially poisoned chalice

Biochemical Society Transactions

Volumn 41, Issue 4, 2013, Pages 1083-1088

  Claus, Jeroen ^a   Cameron, Angus J M ^b   Parker, Peter J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; Epidermal growth factor receptor (EGFR); Kinase; Kinase inhibitor; Protein kinase A (PKA); Pseudokinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; ERLOTINIB; LAPATINIB; PROTEIN KINASE; PROTEIN STRAD ALPHA; PSEUDOKINASE; PSEUDOKINASE ILK; PSEUDOKINASE JAK2; PSEUDOKINASE JH2; PSEUDOKINASE VRK3; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

BIOCATALYSIS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84880529916     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20130078     Document Type: Article

References (34)

1. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934
2. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
3. Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A. and McGuire, W. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182
4. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. and Kinzler, K.W. (2013) Cancer genome landscapes. Science 339, 1546-1558
5. Nowell, P. and Hungerford, D. (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497
6. Rowley, J.D. (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293
7. Zhang, J., Yang, P.L. and Gray, N.S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39
8. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954
9. Boudeau, J., Miranda-Saavedra, D., Barton, G.J. and Alessi, D.R. (2006) Emerging roles of pseudokinases. Trends Cell Biol. 16, 443-452
10. Jura, N., Shan, Y., Cao, X., Shaw, D.E. and Kuriyan, J. (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. U.S.A. 106, 21608-21613
11. Shi, F., Telesco, S.E., Liu, Y., Radhakrishnan, R. and Lemmon, M.A. (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. U.S.A. 107, 7692-7697
12. 2+-independent neurexin kinase. Cell 133, 328-339
13. Brennan, D.F., Dar, A.C., Hertz, N.T., Chao, W.C.H., Burlingame, A.L., Shokat, K.M. and Barford, D. (2011) A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472, 366-369
14. Fukuda, K., Gupta, S., Chen, K., Wu, C. and Qin, J. (2009) The pseudoactive site of ILK is essential for its binding to α-parvin and localization to focal adhesions. Mol. Cell 36, 819-830
15. Scheeff, E.D., Eswaran, J., Bunkoczi, G., Knapp, S. and Manning, G. (2009) Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17, 128-138
16. Bandaranayake, R.M., Ungureanu, D., Shan, Y., Shaw, D.E., Silvennoinen, O. and Hubbard, S.R. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754-759
17. Zeqiraj, E., Filippi, B.M., Deak, M., Alessi, D.R. and Van Aalten, D.M.F. (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326, 1707-1711
18. Gibbs, C.S. and Zoller, M.J. (1991) Rational scanning mutagenesis of a protein kinase identifies functional regions involved in catalysis and substrate interactions. J. Biol. Chem. 266, 8923-8931
19. Hanks, S.K., Quinn, A.M. and Hunter, T. (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52
20. Knighton, D.R., Zheng, J.H., Ten Eyck, L.F., Xuong, N.H., Taylor, S.S. and Sowadski, J.M. (1991) Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 414-420
21. Zeqiraj, E., Filippi, B.M., Goldie, S., Navratilova, I., Boudeau, J., Deak, M., Alessi, D.R. and Van Aalten, D.M.F. (2009) ATP and MO25α regulate the conformational state of the STRADα pseudokinase and activation of the LKB1 tumour suppressor. PLoS Biol. 7, e1000126
22. Lange, A., Wickström, S.A., Jakobson, M., Zent, R., Sainio, K. and Fässler, R. (2009) Integrin-linked kinase is an adaptor with essential functions during mouse development. Nature 461, 1002-1006
23. Baselga, J. and Swain, S.M. (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9, 463-475
24. Zhang, X., Gureasko, J., Shen, K., Cole, P.A. and Kuriyan, J. (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149
25. Stamos, J., Sliwkowski, M. and Eigenbrot, C. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265-46272
26. Davis, M.I., Hunt, J.P., Herrgard, S., Ciceri, P., Wodicka, L.M., Pallares, G., Hocker, M., Treiber, D.K. and Zarrinkar, P.P. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051
27. Bublil, E.M., Pines, G., Patel, G., Fruhwirth, G., Ng, T. and Yarden, Y. (2010) Kinase-mediated quasi-dimers of EGFR. FASEB J. 24, 4744-4755
28. Cameron, A.J.M., Escribano, C., Saurin, A.T., Kostelecky, B. and Parker, P.J. (2009) PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat. Struct. Mol. Biol. 16, 624-630
29. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B.J., Anderson, D.J., Alvarado, R., Ludlam, M.J.C., Stokoe, D., Gloor, S.L., Vigers, G. et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435
30. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M. and Rosen, N. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430
31. McKay, M.M., Ritt, D.A. and Morrison, D.K. (2011) RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. Curr. Biol. 21, 563-568
32. Hu, J., Yu, H., Kornev, A.P., Zhao, J., Filbert, E.L., Taylor, S.S. and Shaw, A.S. (2011) Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl. Acad. Sci. U.S.A. 108, 6067-6072
33. Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O.N., Xu, C.-F., Neubert, T.A., Skoda, R.C., Hubbard, S.R. and Silvennoinen, O. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18, 971-976
34. Wood, E.R. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659